Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin
The ERMBT IV has been shown to predict a significant portion of the interindividual variation in the disposition of some CYP3A4 substrates, including the immunosuppressant cyclosporine (INN, ciclosporin), 5 the nonnucleoside reverse transcriptase inhibitor delavirdine 6 and, most recently, the chemotherapeutic agent docetaxel. 7 In addition, the ERMBT IV appears to be sensitive to the effects of CYP3A4 inducers, such as glucocorticoids and rifampin (INN, rifampicin), 1, 8, 9 and especially to a variety of CYP3A4 inhibitors. Ketoconazole, clarithromycin, amprenavir, delavirdine, and troleandomycin have all been shown to reduce average ERMBT IV results by at least 60% in comparison with baseline values. 1, 6, [10] [11] [12] These findings suggest that this test could be particularly useful in the prediction of drug-drug interactions in which CYP3A4 is a major determinant.
In addition to being highly expressed in the liver, CYP3A4 is highly expressed in the small intestine. 13 The ERMBT IV result would, therefore, appear to reflect only hepatic CYP3A4 activity because intravenous administration should avoid significant metabolism by the gut. Indeed, the average rate at which 14 CO 2 was exhaled by patients with severe liver disease was just 16% of that in subjects with normal liver function, 14 and 14 CO 2 production was negligible during the anhepatic phase of a liver transplant operation. 15 Therefore, if the goal were to assess aggregate intestinal and hepatic CYP3A4 activity, the ERMBT IV alone would not suffice. Accordingly, we developed an oral stable isotope ( 13 C)-labeled formulation of the ERMBT (ERMBT oral ). We began our validation of this test by examining the effects of a prototypical CYP3A4 inhibitor (troleandomycin) and inducer (rifampin) on the rate of 13 CO 2 production. This investigation further revealed that mechanisms in addition to CYP3A4-mediated metabolism govern the erythromycin-rifampin interaction.
MATERIAL AND METHODS Materials and chemicals
Uncoated track-etched polyethylene terephthalate inserts and murine laminin were purchased from Collaborative Biochemical Products (Bedford, Mass). Dulbecco's modified Eagle medium with high glucose, Hanks balanced salt solution, and nonessential amino acids were purchased from Invitrogen (Carlsbad, Calif). Fetal bovine serum was purchased from Hyclone (Logan, Utah). Gentamicin (in lieu of penicillinstreptomycin), dl-␣-tocopherol, sodium selenite, zinc sulfate, unlabeled digoxin, unlabeled erythromycin, troleandomycin, and oleandomycin were purchased from Sigma Chemical Co (St Louis, Mo). [ 3 H]Digoxin (19 Ci/mmol) was purchased from New England Nuclear (Boston, Mass). [ 14 C-N-methyl]erythromycin (54.5 mCi/mmol) was purchased from Metabolic Solutions, Inc (Nashua, NH). [ 13 C 2 -N,N-methyl]erythromycin was obtained from Cambridge Isotope Laboratories, Inc (Andover, Mass). Before use, the bulk material was analyzed by high-resolution mass spectrometry (to determine identity), combustion isotope ratio mass spectrometry (to determine 13 C enrichment), and HPLC (to determine purity); weighed in 500-mg quantities; and then placed into unit-dose capsules. LY335979 [full chemical name, (2R-anti-5-{3-[4-(10,11-difluoromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy} quinoline trihydrochloride)], a selective P-glycoprotein inhibitor, 16 was a gift from Eli Lilly and Co (Indianapolis, Ind). All other chemicals and reagents were of tissue culture or reagent grade when appropriate.
Reproducibility of the ERMBT oral
To evaluate the reproducibility of the ERMBT oral , a preliminary investigation was conducted in 15 healthy nonsmoking volunteers who were maintained on their usual diets. The test was administered to each subject on 3 separate occasions-days 1, 2, and 8. On the morning of each day, a single oral dose of [ 13 C 2 -N,Nmethyl]erythromycin (500 mg, equivalent to 1.14 mmol erythromycin base), was given with 3 Maalox (Novartis, East Hanover, NJ) tablets (to neutralize stomach acid and minimize erythromycin degradation) and 8 ounces of water. The subject was instructed to exhale through a Quintron disposable modified Haldane-Priestley tube (Milwaukee, Wis) that was connected to a plastic bag. Breath samples were collected into Exetainer breath storage tubes (Labco Ltd, High Wycombe, United Kingdom) just before dose administration and at 30-minute intervals for 3 hours thereafter. Each breath sample was analyzed for 13 CO 2 content by mass spectrometry (see "Analytic procedures").
Human subject study
Subjects. A separate group of healthy nonsmoking volunteers (5 women and 9 men; age range, 21-43 years; weight range, 47-83 kg) participated in the study. Before enrollment, each subject had normal findings after a routine physical examination and laboratory tests that included hematologic testing, serum chemical CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 72, NUMBER 5 testing, and urinalysis. In addition, none of the women were of childbearing potential. No subject was taking other medications, either prescription or nonprescription, for at least 2 weeks before and during the study, and no subject had known allergies to macrolide antibiotics or rifampin. All subjects were instructed to refrain from consuming grapefruit-containing products and alcoholic beverages beginning at least 2 days before and during the course of the study. The University of Michigan Institutional Review Board approved the study, and all subjects provided written informed consent.
Study design. This study consisted of 3 phases, each preceded by an overnight fast. On the morning of the first phase (day 1), an indwelling heparin-lock catheter was placed into an arm vein of each subject for blood collection. The subject was then administered an intravenous dose of [ 14 C-N-methyl]erythromycin (0.07 mol, 3 Ci) into the opposite arm. Subsequently, a single oral dose of [ 13 C 2 -N,N-methyl]erythromycin was administered. Blood (5 mL) was collected just before oral drug administration and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 10 hours thereafter. Plasma was separated from blood cells by centrifugation and was stored at Ϫ20°C, pending analysis for erythromycin. The second phase began the following morning (day 2) when the subject was given a single oral dose (500 mg) of troleandomycin (TAO; Pfizer Inc, New York, NY). Two hours later and at the same times used for the previous day's tests, the ERMBT IV and ERMBT oral were administered. Blood sample collections were repeated. Phase 3 began the next morning (day 3) or up to 7 days later when the subject was given a single oral dose (600 mg) of rifampin (Rifadin; Aventis Pharmaceuticals, Kansas City, Mo). For the next 6 consecutive mornings, the subject was given the same oral dose of rifampin. On the day after the final rifampin dose, both ERMBTs and blood sample collections were repeated. During all 3 phases, the subject was not allowed to eat until after the 4-hour blood sample was drawn.
Intravenous and oral erythromycin breath tests. For the ERMBT IV , before and 20 minutes after injection, each subject was instructed to exhale through a tube into a scintillation vial that contained a CO 2 trapping solution (hyamine and ethanol) as described previously. 1 Expired 14 CO 2 was measured by liquid scintillation counting. Results are expressed as the percentage of administered 14 C exhaled during the first hour after injection, as estimated by a single breath collection at 20 minutes. 17 The ERMBT oral was administered and breath was collected during the ensuing 3 hours exactly as described for the reproducibility study. Results are expressed as the percentage of the dose exhaled as 13 CO 2 during the interval from 0 to 3 hours.
Analytic procedures
13 CO 2 in breath after ERMBT oral administration. The amount of 13 CO 2 in the breath storage tubes was determined by use of a Europa Scientific 20/20 gas isotope ratio mass spectrometer (Cincinnati, Ohio). The ratio of 13 CO 2 to 12 CO 2 (mass 45 and 44, respectively) was measured in each sample and compared with a reference gas (5% CO 2 , balanced with 75% N 2 and 20% O 2 ). The reference gas was calibrated with international standards. The units of measurement were atom percentage of 13 C expired (APE) and were defined by the following equation:
Standards of carbon dioxide gas at 3 different levels of APE were analyzed before and after each daily run to assess instrument performance. The analytic precision of the instrument was 0.0001 APE. The APE values from each breath sample were used to calculate the percentage of the dose recovered during each time interval. The area under the APE-versus-time curve for each of the 0-to 1-, 1-to 2-, and 2-to 3-hour intervals (AUC breath ) was calculated by use of the linear trapezoidal method. The percentage of the dose metabolized during each 1-hour interval was calculated as the ratio of the total amount of 13 C recovered (in millimoles) in that interval ( 13 C interval ) to the administered dose (1.14 mmol), for which 13 C interval was calculated according to the following equation:
in which BSA is body surface area. The CO 2 production rate was assumed to be 5 mmol CO 2 /min/m 2 BSA.
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Erythromycin in plasma after oral administration. The concentration of erythromycin in plasma was determined by use of HPLC with mass spectrometric detection. Plasma (100 L) was spiked with 300 ng oleandomycin as the internal standard. Samples were mixed by vortex for approximately 10 seconds and then centrifuged for 5 minutes at 14,000g. The supernatant was recovered, and a 5-L aliquot was injected onto a Hewlett Packard 1090 Series II liquid chromatography system (Palo Alto, Calif) coupled to a Sciex API III mass spectrometer (Thornhill, Ontario, Canada). Analytes were separated with a Phenomenex IB-SIL C 18 -BD column (3 m, 3.3 cm ϫ 4.6 mm; Torrance, Calif). The mobile phase, consisting of methanol and 25-mmol/L ammonium acetate (76: 24) , was delivered at a constant flow rate of 1 mL/min. The effluent flowed directly into the electrospray ion source of the mass spectrometer, which was operated in the selected ion monitoring mode. The [MϩH] ϩ ions at mass-to-charge ratios of 736.7 ( 13 C 2 -erythromycin) and 688.7 (oleandomycin) were monitored. A set of 8 nonzero calibration standards that ranged from 20 to 2000 ng/mL and quality control samples at concentrations of 60, 800, and 1700 ng/mL were run during each day of analysis. The calibration curve was linear over the range studied, with a correlation coefficient Ն0.995. Samples with nominal concentrations above the highest calibration standard were diluted and reanalyzed in a subsequent batch. The interassay coefficients of variation for the quality control samples were 10.9%, 3.8%, and 4.1% for the low-, middle-, and high-quality control samples, respectively. The accuracy of the assay ranged from 93% to 99% nominal of the known standard. The low volume injected onto the liquid chromatography-mass spectrometry system did not compromise the chromatography or the ionization of the analytes for the duration of analysis.
Pharmacokinetic analysis
The pharmacokinetics of erythromycin after oral administration were evaluated by use of noncompartmental methods. The terminal elimination rate constant ( Z ) was determined by log-linear regression of at least the last 3 data points from the plasma concentration-time profile. The terminal elimination half-life (t 1/2 ) was calculated as ln2/ Z . The area under the plasma concentration-time curve (AUC) was calculated by use of the linear trapezoidal method and extrapolation to infinite time by dividing the last measured concentration by Z . The apparent oral clearance (CL/F) was calculated as the ratio of dose to AUC. The maximum plasma concentration (C max ) and the time to reach C max (t max ) were obtained by visual inspection of the concentration-time profile.
Evaluation of troleandomycin as an inhibitor of erythromycin transport
Cell culture inserts were coated with the extracellular matrix protein laminin (5 g/cm 2 ), as described previously, 19 onto which the Caco-2 cell clone P27. 19, 20 Incubation medium (serum-free differentiation medium) was freshly prepared and kept at 37°C. LY335979, troleandomycin, and unlabeled digoxin were dissolved as 1000-fold concentrated solutions in dimethyl sulfoxide. [ 3 H]-Digoxin was further diluted in absolute ethanol. Unlabeled erythromycin was dissolved as a 100-fold concentrated solution in ethanol. The contents of 4 single-dose vials of [ 14 C-N-methyl]erythromycin were combined and concentrated (about 30-fold) under a gentle stream of nitrogen to deliver 0.5 Ci of radioactivity per culture insert while minimizing the final concentration of ethanol.
Incubation medium was spiked either with drug(s) or with vehicle (dimethyl sulfoxide or ethanol), or with both, just before its addition to triplicate cultures. As a "preincubation" step, incubation medium (1.5 mL) that contained either troleandomycin, LY335979, or an appropriate vehicle was added to the apical (luminal) chamber of the insert, followed by an equal volume of plain incubation medium to the basolateral chamber. After 30 minutes at 37°C, apical and basolateral media were removed and immediately replaced with the various combinations of erythromycin or digoxin and preincubation compound or vehicle. Final concentrations of troleandomycin, LY335979, dimethyl sulfoxide, and ethanol were 30 mol/L, 0.5 mol/L, 0.1% (vol/vol), and 1% (vol/vol), respectively. Under these conditions, troleandomycin was at the limit of solubility.
To evaluate apical-to-basolateral (A3 B) translocation of erythromycin across the cell monolayers, incubation medium that contained [
14 C]erythromycin (10 mol/L, 0.5 Ci) and one of the preincubation compounds (or vehicle) was added to the apical chamber, followed by incubation medium plus an appropriate vehicle to the basolateral chamber. To evaluate basolateral-to-apical (B3 A) translocation of erythromycin, incubation medium that contained [
14 C]-erythromycin was added to the basolateral chamber, followed by incubation medium that contained one of the preincubation compounds (or vehicle) to the apical chamber. Samples (40 L) were collected from both the apical and basolateral compartments of each insert at 1, 2, 3, and 4 hours after the addition of [
14 C]erythromycin. As a positive control for P-glycoprotein activity, an identical experiment was performed with the P-glycoprotein substrate [ receiving chamber to the sum of radioactivity measured in the dosing and receiving chambers. Efflux ratiosmeasures of net secretion-were calculated as the ratio of the percentage of radiolabeled drug translocated into the basolateral chamber to that translocated into the apical chamber during the 4-hour period.
Statistical analysis
All statistical analyses were performed with use of StatView (version 5.0.1; SAS Institute Inc, Cary, NC). For the human subject study, nonparametric methods were used because the data were not assumed to be normally distributed. The Wilcoxon signed-rank test was used to determine whether the effects of troleandomycin or rifampin treatment on the various ERMBT and pharmacokinetic measurements were significantly different from baseline (significance level of .05). Relationships between the ERMBT IV and ERMBT oral results and between each ERMBT result and erythromycin CL/F or C max were assessed from the Spearman correlation coefficient (r S ), which was considered to be significant if the P value was Ͻ.05. For the cell culture studies, the unpaired t test with equal variance was used to determine whether a difference existed between vehicle-treated and troleandomycin-or LY335979-treated culture inserts (significance level of .05).
RESULTS

Intrasubject variation in the ERMBT oral
A preliminary investigation was conducted in 15 healthy volunteers to evaluate the interday variability in the ERMBT oral within a subject. Fig 1 shows the test result, expressed as the percentage of the dose oxidized during the 0-to 3-hour breath collection interval, for each subject on each of 3 days. Virtually identical patterns ensued if the test result were based on the 1-to 3-or 2-to 3-hour collection interval (data not shown). Within-subject variation was generally good (median, 19%; range, 9% to 105%). We therefore proceeded with our evaluation of the ERMBT oral in a separate group of healthy volunteers. Our objective was to compare the effects of the CYP3A4 modulators troleandomycin and rifampin on the ERMBT IV result, the ERMBT oral result, and on oral erythromycin pharmacokinetics.
ERMBT IV
In the current group of subjects (n ϭ 14), the median ERMBT IV result at baseline was 1.85 and varied 3-fold (range, 1.03-2.97; Fig 2, A) . After troleandomycin administration, the ERMBT IV result markedly decreased in all subjects; the median test result was 0.09 (range, 0.05-0.22) and was significantly lower than that at baseline (P ϭ .001; Fig 2, A) . After rifampin treatment, the ERMBT IV result increased in all subjects, from 1.4-to 5.7-fold above baseline (Fig 2, A) . The median test result significantly increased from baseline (to 4.23; P ϭ .001), and individual results ranged from 2.49 to 5.87.
ERMBT oral
At baseline, the median (1.91) and range (0.63-2.66) in the ERMBT oral result, expressed as the percentage of 13 CO 2 exhaled during the 0-to 3-hour interval (Fig 2,  B) , were comparable with those observed in our preliminary investigation of 15 healthy subjects (Fig 1) . After troleandomycin administration, as with the ERMBT IV result, the ERMBT oral result decreased in all subjects, and the median value (0.57; range, 0.00-0.83) was significantly lower than that at baseline (P ϭ .001; Fig 2, B) . After rifampin treatment, unlike with the ERMBT IV result, the ERMBT oral result increased (Ն1.3-fold above baseline) in only half of the subjects, and no more than 1.7-fold (Fig 2, B) . For the remaining subjects, the oral test result was unchanged or was even decreased (by as much as 90%) from baseline. Consequently, the median ERMBT oral result (1.97; range, 0.20-3.69) was not significantly different from that at baseline (P ϭ .30).
Oral erythromycin pharmacokinetics
Two representative plasma concentration versus time profiles for erythromycin after administration of the ERMBT oral for all 3 phases of the study are shown in Fig 3, A and C , in which the rank order of AUC values (troleandomycin Ͼ baseline Ͼ rifampin) was readily apparent. Table I displays the median values and ranges of the various pharmacokinetic measures (t max , C max , Z , and CL/F) determined for each phase of the study, and those at baseline agreed with previous reports. 21, 22 The C max was generally achieved within 1.5 to 2.5 hours and, compared with baseline, the median t max was unchanged after troleandomycin (P ϭ .19) and rifampin (P ϭ .37) treatment. Compared with baseline, the median C max significantly increased with troleandomycin treatment (1.34 versus 2.92 mg/L; P ϭ .001) and significantly decreased with rifampin treatment (to 0.72 mg/L; P ϭ .04). The median Z significantly decreased from baseline with troleandomycin treatment (0.35 versus 0.24 h Ϫ1 ; P ϭ .006) but remained unchanged after rifampin treatment (0.38 h Ϫ1 ; P ϭ .70). These values corresponded to terminal t 1/2 values of 2.0 hours (baseline), 2.9 hours (troleandomycin), and 1.8 hours (rifampin). The percentage of total AUC extrapolated from 10 hours to infinite time was always Ͻ30%. The median erythromycin oral clearance displayed a pattern similar to the ERMBT IV result; that is, CL/F decreased significantly (P ϭ .001), by more than 70% compared with baseline, after troleandomycin administration (96 versus 26 L/h) and significantly increased (P ϭ .013) after rifampin treatment (to 197 L/h). There was no change in the variability in erythromycin CL/F when adjusted for body weight for all 3 phases of the study (data not shown).
Corresponding representative ERMBT oral profiles (percentage of 13 C exhaled versus time) are presented in Fig 3, B and D. For the subject shown in Fig 3, B , the rank order of breath AUC values (rifampin Ͼ baseline Ͼ troleandomycin) was opposite that for plasma AUC values (Fig 3, A) . This would be expected if the reduction and elevation in erythromycin plasma levels resulted solely from induction and inhibition, respectively, of CYP3A4. For the subject shown in Fig 3, D, however, the rank order of breath AUC values (baseline Ͼ troleandomycin Ͼ rifampin) was not opposite that for plasma AUC values (Fig 3, C) . This paradoxic scenario occurred in half of the 14 subjects.
Correlation analyses
Although the ERMBT IV and ERMBT oral results showed similar trends at baseline and with troleandomycin treatment, there was no rank-order correlation between the 2 test results within either treatment group (r S ϭ 0.47 and r S ϭ Ϫ0.18, respectively; P Ն .09). Not surprisingly, there was no association between the 2 ERMBT results within the rifampin phase (r S ϭ Ϫ0.002; P ϭ .99). There were no correlations between erythromycin CL/F and either ERMBT result or between erythromycin C max and the ERMBT IV result within each treatment group (P Ն .05). For the association between erythromycin C max and the ERMBT oral result, there was a positive but insignificant trend at baseline (r S ϭ 0.53; P ϭ .06), no correlation with troleandomycin treatment (r S ϭ Ϫ0.23; P ϭ .41), and a significant correlation with rifampin treatment (r S ϭ 0.64; P ϭ .02; Fig 4) . 
Troleandomycin is not an inhibitor of erythromycin transport
To determine whether troleandomycin may have confounded the interpretation of our in vivo results (by altering erythromycin transport), we conducted an in vitro experiment using [ 14 C-N-methyl]erythromycin and the human intestinal cell line Caco-2, which is known to express P-glycoprotein (and other transporters). As a positive control for P-glycoprotein activity, an identical experiment was conducted with use of the established P-glycoprotein probe substrate digoxin. 23, 24 For all culture inserts, at least 90% of the initial amount of radioactivity added was recovered in the media collected from the apical and basolateral chambers at the end of the 4-hour incubation. Compared with vehicletreated culture inserts, troleandomycin had no effect on the mean percentage of erythromycin translocated in both the A3 B direction (0.5% versus 0.5%; P ϭ .34) and B3 A direction (48.9% versus 47.0%; P ϭ .20; Fig  5, A and B) . In contrast, the selective P-glycoprotein inhibitor LY335979 significantly increased mean A3 B translocation of erythromycin (to 6.4%; P Ͻ .0001) and decreased mean B3 A translocation of erythromycin (to 12.5%; P Ͻ .0001; Fig 5, C) . Similarly, compared with vehicle-treated cultures, the average efflux ratio of erythromycin was unaffected by troleandomycin (99.8 versus 87.9; P ϭ .11) but was significantly decreased by LY335979 (to 1.96; P Ͻ .0001). Results with digoxin-treated cultures (Fig 5, D , E, and F) were qualitatively identical to erythromycintreated cultures with statistically similar trends. Compared with erythromycin, the mean B3 A translocation for digoxin was similar (43.4% and 44.6% for vehicleand troleandomycin-treated cultures, respectively), whereas the mean A3 B translocation was 5-to 7-fold greater (3.4% and 2.5% for vehicle-and troleandomycin-treated cultures, respectively). Consequently, the mean efflux ratio for digoxin was roughly 5-fold lower (15.5 and 19.5 for vehicle-and troleandomycin-treated cultures, respectively) than that for erythromycin. LY335979 inhibited both A3 B and B3 A digoxin translocation so that the percentage of the dose translocated in each direction was similar to that for erythromycin (8.7% and 12.1% for A3 B and B3 A, respectively), yielding an efflux ratio (1.44) similar to that for erythromycin.
DISCUSSION
The overall goal of our study was to develop an oral erythromycin breath test that was capable of assessing aggregate liver and intestinal CYP3A4 activity. Analogous to the ERMBT IV , and with no diet restrictions, the oral 13 C-labeled formulation displayed good intrasubject reproducibility for percentage of 13 CO 2 exhaled in breath during the 0-to 3-hour interval after administration (Fig 1) . The larger values for interday variation observed in the 2 subjects with the lowest values (Ͻ0.5%) were attributed to the greater sensitivity of low values to the natural fluctuations in the ratio of 13 C to 12 C in expired CO 2 , which can be influenced by food and exercise. 25 Accordingly, we proceeded with our evaluation of this new test, which was to compare the effects of prototypical CYP3A4 modulators on the ERMBT oral result, on the ERMBT IV result, and on oral erythromycin disposition.
As expected, pretreatment with a single oral dose of the CYP3A4 mechanism-based inhibitor troleandomycin significantly decreased the median rate of labeled CO 2 production relative to baseline, regardless of the route of erythromycin administration. Compared with intravenous administration, the apparent weaker degree of inhibition of erythromycin demethylation after oral administration (95% versus 70%) may have arisen from the time course of troleandomycin inhibition. With the ERMBT IV , a single breath sample was collected 20 minutes after injection, or 2 hours and 20 minutes after troleandomycin was given. With the ERMBT oral , breath samples were continually collected until 3 hours after drug administration, or 5 hours after troleandomycin was given. With the ERMBT IV we have found that inhibition of CYP3A4 by a single oral dose of troleandomycin peaks between 2 and 3 hours, then wanes thereafter (unpublished observations). The reduced magnitude of inhibition observed with the ERMBT oral may therefore simply have reflected a "wearing off" of the troleandomycin effect. As with the ERMBTs, troleandomycin treatment significantly decreased the median CL/F of erythromycin (to less than one third of that at baseline), consistent with the premise that troleandomycin interacts with erythromycin by inhibition of CYP3A4, which could occur in the intestine or liver.
Rifampin treatment doubled the median rate of 14 CO 2 exhaled from the ERMBT IV , which was anticipated because rifampin is a well-established and potent inducer of CYP3A4. Likewise, the median CL/F of erythromycin doubled and, together with the ERMBT IV result, was consistent with hepatic CYP3A4 induction as a mechanism that underlies the oral erythromycinrifampin interaction. Unlike troleandomycin, however, rifampin did not alter the median production of 13 CO 2 from the ERMBT oral . That is, in spite of a marked interaction between rifampin and oral erythromycin, the total demethylation of erythromycin unexpectedly appeared to be unchanged relative to baseline. One explanation is that rifampin treatment indeed resulted in increased erythromycin N-demethylation in the intestine, but this was not reflected in increased production of breath 13 CO 2 . This could occur if the 13 C-labeled formaldehyde generated in the intestine did not undergo the same fate (in terms of one carbon pool kinetics) as formaldehyde generated in the liver. This seems to be unlikely, however, because the enzymes involved in one carbon pool kinetics are believed to be ubiquitous. Another unforeseen finding was the positive association between erythromycin C max and the ERMBT oral result at baseline and with rifampin treatment (Fig 4) . If erythromycin C max were assumed to be largely a reflection of first-pass metabolism, an association between a high rate of 13 CO 2 production and a low C max would be expected. However, the opposite trend occurred (a high rate of 13 CO 2 production was associated with a high C max ), indicating that CYP3A4-mediated first-pass metabolism (in the intestine or liver) is not the major determinant of erythromycin C max , particularly during rifampin treatment. Collectively, the lack of effect of rifampin on the median rate of erythromycin demethylation (as indicated by the ERMBT oral ) and the positive association between erythromycin C max and the ERMBT oral result strongly imply that a mechanism(s) in addition to CYP3A4 induction must account for the oral erythromycin-rifampin interaction. One plausible mechanism may involve the transmembrane secretory pump P-glycoprotein. P-glycoprotein, the product of the multidrug resistance gene MDR1, is an apically directed and adenosine triphosphate-dependent transporter that was first identified in human cancer cells; it acts to extrude certain chemotherapeutic agents from the cell and to render the agent ineffective.
26 P-glycoprotein has also been detected in normal human tissues, including capillary endothelial cells of the brain, epithelial cells (brush border) of the renal tubule and intestine, and the canalicular membrane of hepatocytes. 26, 27 Because of its luminal-canalicular location in these tissues, P-glycoprotein functions to limit brain uptake, to reduce absorption, and to enhance the renal, intestinal, and biliary excretion of its substrates (reviewed by Ambudkar et al 26 ) . Along with numerous other drugs and xenobiotics, erythromycin has been shown to be a substrate for P-glycoprotein, and a pronounced role for this efflux pump in erythromycin disposition in vivo in rats has been reported. 28 In humans, rifampin is an inducer not only of intestinal (and hepatic) CYP3A4 but also of intestinal P-glycoprotein. 24, 29 Although not confirmed by direct intestinal biopsy measurements in this study, we can assume that rifampin treatment induced both proteins. Consequently, the reduction in oral erythromycin AUC by rifampin was likely largely the result of an increase in intestinal P-glycoprotein levels. The lack of effect of rifampin on the median ERMBT oral result could therefore be explained if induction of P-glycoprotein resulted in roughly a 50% decrease in the median amount of erythromycin absorbed from the gut lumen. This alone would explain why the median AUC value of erythromycin after rifampin administration was approximately half of the median erythromycin AUC at baseline (2.5 versus 5.2 mg ⅐ h/L). A 2-fold induction in CYP3A4 activity (as reflected in the 2-fold increase in the median ERMBT IV result) would therefore explain why the median ERMBT oral result was similar to that observed at baseline. In other words, the median rate of 13 CO 2 expired from the ERMBT oral remained un-
Fig 4.
Spearman rank correlation between the ERMBT oral result and plasma erythromycin maximum plasma concentration (C max ) at baseline after troleandomycin (TAO) treatment (single dose of 500 mg) and after rifampin treatment (600 mg daily for 7 days) in 14 healthy subjects. changed after rifampin treatment because CYP3A4 induction (in the intestine and liver) was offset by the reduced delivery of erythromycin to the enzyme (because of reduced absorption).
P-glycoprotein in organs other than the intestine (eg, kidney, brain, and liver) may have also influenced erythromycin disposition. However, the percentage of an oral erythromycin dose excreted unchanged in the urine (2% to 5%) 30 is minimal, making a role for renal P-glycoprotein unlikely. Although erythromycin is not detected in normal cerebrospinal fluid and brain tissue, 30 perhaps suggesting a role for cerebral P-glycoprotein, it seems to be intuitively unlikely that P-glycoprotein in the central nervous system would have a major impact on erythromycin disposition. A role for hepatic P-glycoprotein, however, cannot be ruled out. When mdr1a nullizygous (Ϫ/Ϫ) and mdr1a/1b (Ϫ/Ϫ) mice received an intravenous injection of [ 14 C-N-methyl]erythromycin, the breath 14 CO 2 AUC was 1.5-and 1.9-fold greater, respectively, compared with that for the wild-type counterparts, despite having equivalent levels of hepatic CYP3A4. 31 These observations raised the possibility that hepatic P-glycoprotein influenced CYP3A4-mediated metabolism. Although induction of hepatic P-glycoprotein by rifampin may have occurred and may have influenced the current observations, it would be expected that such induction would have comparable effects on both the oral and ERMBT IV results. Hepatic P-glycoprotein therefore would not account for the discrepancy between the ERMBT oral and ERMBT IV results.
Troleandomycin did not alter the transport of erythromycin or of the P-glycoprotein substrate digoxin in monolayers of the human intestinal cell line Caco-2, suggesting that the effects observed in vivo with troleandomycin pretreatment were the result of selective CYP3A4 inhibition. We therefore concluded that CYP3A4-mediated metabolism represents a major pathway for the elimination of erythromycin in uninduced individuals. The lack of effect of troleandomycin on P-glycoprotein activity also explained why the changes in the ERMBT IV result, the ERMBT oral result, and the various oral erythromycin pharmacokinetic measurements were the same as the predicted changes.
Rivory et al 32 recently reported that the ERMBT IV result did not correlate with the systemic clearance of erythromycin in 16 adult patients with cancer. Although we did not directly assess the systemic clearance of erythromycin in this study, it is interesting that the median Z of erythromycin was only modestly reduced after CYP3A4 inhibition (by troleandomycin) and was unaffected after CYP3A4 induction (by rifampin; Table I ). Assuming that the 2 modulators of CYP3A4 did not alter the (terminal) volume of distribution of erythromycin, these observations support the contention that CYP3A4-mediated metabolism is not rate limiting in the systemic clearance of erythromycin. It should be noted that the contribution of other non-CYP3A4-mediated pathways in the systemic clearance of erythromycin would not invalidate the ERMBT IV as a measure of hepatic CYP3A4 activity, unless such pathways significantly altered the hepatic concentration of erythromycin 20 minutes after injection (ie, when the single breath sample is collected). 33 In conclusion, because the oral erythromycin breath test does not appear to simply reflect aggregate intestinal and hepatic CYP3A4 activity, this test would not be suitable as an in vivo CYP3A4 phenotyping probe. However, a key finding during the course of the evaluation of this test was that the oral erythromycinrifampin interaction was not solely the result of CYP3A4 induction and likely also reflected intestinal P-glycoprotein induction. This would not have surfaced if we had examined only erythromycin pharmacokinetics. To our knowledge, the erythromycin-rifampin interaction represents the first example in which P-glycoprotein appears to be a major locus for an interaction that involves a substrate administered in half-gram quantities. It therefore seems that P-glycoprotein can serve as a relatively high-capacity xenobiotic transporter in vivo. Although erythromycin and rifampin are rarely prescribed together, results from this study may well apply to drug-rifampin interactions that involve other CYP3A4 and P-glycoprotein substrates similarly given in large quantities (eg, the human immunodeficiency virus protease inhibitors saquinavir, indinavir, and amprenavir). What may appear to be consistent with CYP3A4-mediated metabolism may also reflect P-glycoprotein-mediated efflux.
